Achievements and challenges of the Sakigake designation system in Japan
- 10 March 2021
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (10) , 4027-4035
Abstract
The Sakigake designation system (Sakigake) has been launched to encourage the pioneered development of innovative new medical products for the effective treatment of severe illness in Japan, which allows leveraging the several advantages in prioritized consultation, rapid review, premium drug pricing and extended data‐protection period. We retrospectively analysed the Sakigake products including drugs and regenerative medical products to clarify the achievements and the future issues in this system. From April 2015 to August 2020 (the first 5‐year trial period of Sakigake), 37 products were designated, and 10 of those were approved in Japan in which 7 new active substances achieved the first‐in‐world approvals. Oncology, neurology and cardiovascular disease were the major therapeutic areas, and those 3 accounted for 75.7% of all products. Sakigake achieved some first‐in‐world approvals by the Pharmaceuticals and Medical Devices Agency/the Ministry of Health, Labor and Welfare of innovative new medical products, although in some therapeutic areas, there remains room in stimulating drug development.Keywords
This publication has 9 references indexed in Scilit:
- Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory AnalysisClinical Pharmacology & Therapeutics, 2020
- Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort studyBMJ, 2020
- Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory StatusTherapeutic Innovation & Regulatory Science, 2020
- Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and JapanInternational Journal of Molecular Sciences, 2019
- The Current Status of Sakigake Designation in Japan, PRIME in the European Union, and Breakthrough Therapy Designation in the United StatesTherapeutic Innovation & Regulatory Science, 2017
- Closing the drug lag for new drug submission and review in Japan: An industry perspectiveClinical Pharmacology & Therapeutics, 2015
- Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in JapanClinical Pharmacology & Therapeutics, 2013
- Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situationsJournal of Clinical Pharmacy and Therapeutics, 2010
- Delays in New Drug Applications in Japan and Industrial R&D StrategiesClinical Pharmacology & Therapeutics, 2009